Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP17A1 | P05093 | 5/20 | 0.69 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.69 |
| ▸ | CYP2C19 | P33261 | 4/20 | 0.69 |
| ▸ | CYP26A1 | O43174 | 15/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 14/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9896560 | 0.90 | CYP17A1 (0.56) | CYP17A1CYP2C9CYP2C19CYP26A1CYP3A4 | |
| SCHEMBL9894973 | 0.86 | CYP17A1 (0.50) | CYP17A1CYP2C9CYP2C19CYP26A1CYP3A4 | |
| SCHEMBL9895652 | 0.85 | CYP17A1 (0.53) | CYP17A1CYP2C9CYP2C19CYP26A1CYP3A4 | |
| SCHEMBL12500160 | 0.82 | CYP17A1 (1.00) | CYP17A1CYP2C9CYP2C19CYP26A1CYP3A4 | |
| SCHEMBL9895460 | 0.82 | CYP2C9 (0.50) | CYP17A1CYP2C9CYP2C19 | |
| SCHEMBL9896161 | 0.81 | CYP17A1 (0.67) | CYP17A1CYP2C9CYP2C19CYP26A1CYP3A4 | |
| SCHEMBL9896985 | 0.81 | CYP17A1 (0.53) | CYP17A1CYP2C9CYP2C19CYP26A1CYP3A4 | |
| SCHEMBL9945352 | 0.78 | CYP2C19 (0.49) | CYP17A1CYP2C9CYP2C19CYP26A1CYP3A4 | |
| SCHEMBL9945351 | 0.76 | CYP17A1 (0.46) | CYP17A1CYP2C9CYP2C19CYP26A1CYP3A4 | |
| SCHEMBL9965157 | 0.76 | CYP17A1 (0.43) | CYP17A1CYP2C9CYP2C19CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2651905-B1 | METALLOENZYME INHIBITOR COMPOUNDS | INNOCRIN PHARMACEUTICALS INC (US) | 2017-07-19 | — | — | EP | claimed |
| US-8669274-B2 | Metalloenzyme inhibitor compounds | VIAMET PHARMACEUTICALS, INC. (US) | 2014-03-11 | — | — | US | claimed |
| US-20120149729-A1 | METALLOENZYME INHIBITOR COMPOUNDS | VIAMET PHARMACEUTICALS, INC. (US) | 2012-06-14 | — | — | US | claimed |
| EP-2651905-B1 | METALLOENZYME INHIBITOR COMPOUNDS | INNOCRIN PHARMACEUTICALS INC (US) | 2017-07-19 | — | — | EP | disclosed |
| EP-2651905-B1 | METALLOENZYME INHIBITOR COMPOUNDS | INNOCRIN PHARMACEUTICALS INC (US) | 2017-07-19 | — | — | EP | disclosed |
| US-8669274-B2 | Metalloenzyme inhibitor compounds | VIAMET PHARMACEUTICALS, INC. (US) | 2014-03-11 | — | — | US | disclosed |
| US-8669274-B2 | Metalloenzyme inhibitor compounds | VIAMET PHARMACEUTICALS, INC. (US) | 2014-03-11 | — | — | US | disclosed |
| US-8669274-B2 | Metalloenzyme inhibitor compounds | VIAMET PHARMACEUTICALS, INC. (US) | 2014-03-11 | — | — | US | disclosed |
| EP-2651905-A2 | METALLOENZYME INHIBITOR COMPOUNDS | Viamet Pharmaceuticals, Inc. (US) | 2013-10-23 | — | — | EP | disclosed |
| WO-2012082746-A2 | METALLOENZYME INHIBITOR COMPOUNDS | VIAMET PHARMACEUTICALS, INC. (US) | 2012-06-21 | — | — | WO | disclosed |
| WO-2012082746-A2 | METALLOENZYME INHIBITOR COMPOUNDS | VIAMET PHARMACEUTICALS, INC. (US) | 2012-06-21 | — | — | WO | disclosed |
| US-20120149729-A1 | METALLOENZYME INHIBITOR COMPOUNDS | VIAMET PHARMACEUTICALS, INC. (US) | 2012-06-14 | — | — | US | disclosed |
| US-20120149729-A1 | METALLOENZYME INHIBITOR COMPOUNDS | VIAMET PHARMACEUTICALS, INC. (US) | 2012-06-14 | — | — | US | disclosed |
| US-20120149729-A1 | METALLOENZYME INHIBITOR COMPOUNDS | VIAMET PHARMACEUTICALS, INC. (US) | 2012-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120149729-A1 | METALLOENZYME INHIBITOR COMPOUNDS | MMEL1, GPX1, MPO | CYP17A1 649/4885CYP2C9 840/4885CYP2C19 691/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.